
Certificate of Analysis

Analytical Testing Report

REPORT ID	PCA-2026-929975
	SMP-2026-CBF85C
GENERATED	November 6, 2026

SAMPLE IDENTIFICATION

Peptide:	**CAGRILINTIDE 5 MG**	Date Requested:	**October 29, 2026**
Client:	**Summit Peptides**	Date Received in Lab:	**November 1, 2026**
Vendor:	**Not Specified**	Date Tested:	**November 2, 2026**
Lot Number:	**211CG5**	Date Reported:	**November 6, 2026**
Batch Number:	**211CG5**		



EXPECTED CONTENT	5 mg
MASS	5.09 mg
PURITY	99.56%
FILL ACCURACY	101.8%





Appearance	White lyophilized powder
Cap Color	Clear

ANALYTICAL RESULTS

	TEST	METHOD	RESULT	STATUS
1	**Peptide Identity**	FTIR-ATR	Sample infrared spectrum consistent with reference standard with excipients	CONFORMS
2	**Purity**	RP-HPLC-DAD	Main Peak 99.56% RT 17.16 min	CONFORMS
3	**Net Content**	RP-HPLC-DAD	5.09 mg net content quantified using calibrated HPLC against characterized standard	CONFORMS
4	**Endotoxin**	LAL Gel Clot	Not Detected - Threshold 0.06 EU/vial	CONFORMS
5	**Heavy Metals**	Colorimetric Screening	N/A	NOT TESTED

NOTES

RP-HPLC-DAD Agilent AdvanceBio Peptide Mapping 4.6 x 150, 2.7 µm A: 0.1% FA in H2O B: 0.1% FA in ACN 1.0 mL/min 20-60% B @ 40 C Full Spectrum of Main Peak

PACIFICOANALYTICS INC.
COA
INDEPENDENT LABORATORY
VANCOUVER, CANADA

Prepared, reviewed and authorized for release by Pacific COA Analytics.

info@pacificoanalytics.ca

This Certificate of Analysis is provided for informational and research purposes only.

Digital Verification

Important disclaimer and limitations of use: This Certificate of Analysis (COA) is provided for informational and analytical verification purposes only. The data contained herein reflects results obtained from a specific sample batch under controlled laboratory conditions using the specified testing methodologies (e.g., HPLC, MS). Research use only: The product analyzed is intended strictly for laboratory research, in vitro studies, and scientific development. It is not for human or animal consumption, diagnostic application, therapeutic use, or cosmetic formulation. This report is not a Health Canada approval, does not include sterility testing, and is not a claim of suitability for injection. No warranty and liability limitation: This document does not constitute a legal warranty of merchantability, fitness for a particular purpose, or product efficacy. PACIFICOANALYTICS INC. and its affiliates shall not be held liable for any misuse, improper handling, unexpected research outcomes, or third-party interpretations of this data. It is the sole responsibility of the end-user to implement proper handling, storage, and biosafety protocols. Results relate only to the sample tested. This report shall not be reproduced, except in full, without the written approval of PACIFICOANALYTICS INC.